Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR05

Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Melissa Carroll, PharmD, BCPS, Senior Clinical Pharmacist, McKesson/US Oncology Network

Co-Authors: Shannon Hough, PharmD, BCOP, Director, ClinReview and Clinical Content, McKesson/US Oncology Network; Joshua Howell, PharmD, BCOP, Vice President, Pharmacy and Clinical Programs, McKesson/US Oncology Network; Elizabeth Koselke, PharmD, BCOP, Senior Clinical Pharmacist, McKesson/US Oncology Network; Julianna Kula, PharmD, BCOP, Senior Clinical Pharmacist, McKesson/US Oncology Network

BACKGROUND: The impact and role of a clinical pharmacist in a community oncology setting is not well-described in the literature. The US Oncology Network recently implemented a centralized clinical pharmacist review program (ClinReview) to provide oncology clinical pharmacist services to community oncology practices.

OBJECTIVE: To evaluate the impact of remote clinical reviews by oncology pharmacists in community oncology practices.

METHOD: Oncology-trained clinical pharmacists reviewed electronic files for recently placed or modified chemotherapy regimen orders within 4 community oncology practices. The ClinReview pharmacists identified opportunities to modify ordered therapy, based on clinical variables, waste reduction, or financial stewardship. The recommendations were discussed with the treating oncologist at the community oncology practice or modified the regimen, if permitted by approved practice policy. Each pharmacist was appointed at half full-time equivalents. Financial and workload metrics were tracked to monitor the impact of the pharmacist interventions.

RESULTS: In 28 weeks, 2234 reviews were documented, and 1038 (46.5%) required modification by a pharmacist. The recommended modifications included 440 (42%) clinical change, 433 (42%) dose rounding, and 165 (16%) medication substitution. The most common clinical changes included 146 (33%) recommendations for additional monitoring, 137 (31%) modifications to supportive care, and 106 (24%) modifications to anticancer medication dose or frequency. Of these clinical recommendations, 235 (53%) were identified by the ClinReview pharmacist as directly influencing patient safety. The clinical pharmacist was remotely integrated into the care team, influencing complex patient care decisions, such as anticancer regimen selection and dosing. The financial impact of the pharmacist resulted in margin improvements totaling $522,473, and a reduction of $2,766,001 in the total cost of care in medication expenses. The expense of the pharmacists during this period was $117,571. To date, the return on investment for the pharmacists compared with the margin improvement was 444%.

CONCLUSION: Community oncology practices seek to provide high-value care in a resource-constrained model. An oncology clinical pharmacist is a cost-effective and clinically invaluable member of the care team in community oncology practices. Pharmacists identified opportunities to improve medication safety, drug regimen optimization, and demonstrated substantial financial impact on small-scale budgets in community oncology practices. Oncology-trained pharmacists are chemotherapy experts who are well-equipped to review clinical orders in a complex patient population at risk for medication-related adverse effects.

Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: